Docsun Biomed Report on Omicron Variant in the United States
The clinical severity profile of Omicron infection will strongly influence its impact on U.S. hospitalizations and deaths. A study from South Africaexternal icon demonstrates that in the first four weeks of the Omicron variant wave there were lower rates of hospitalization compared to the first four weeks of the Beta- or Delta-dominated waves in Gauteng Province. There was also less severe illness reported for those that were admitted. A study conducted in Canadaexternal icon found that the risk of hospitalization was 54% lower for Omicron cases compared with Delta cases.
Some studies have demonstrated the importance of booster doses in protecting against infection with Omicron, and a lower effectiveness of the primary series of vaccines alone. Current CDC recommendations for vaccines and booster shots are expected to protect against severe illness, hospitalizations, and deaths from infection with the Omicron variant. Therapeutics, including monoclonal antibody treatments and antivirals, are also available for preventing and treating COVID-19 in specific at-risk populations.
Scientists around the world, including researchers at CDC, are working quickly to learn more about the Omicron variant. The recent emergence of Omicron and the fact that Delta is still a circulating variant further emphasize the importance of getting a primary vaccination series and, if eligible, a booster and continuing prevention measures.
Original links to the article: - https://www.cdc.gov/
Docsun Computation Medlab Ltd